Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
NCT00174252
Last updated date
ABOUT THIS STUDY
To estimate the percentage of children with serum IGF-1 > 2 standard deviation (compared to a
child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12
months after initiation of GH treatment.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Fetal Growth Retardation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
4-9 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Chronological age between 4 and 9 years for a boy and 4 and 7 years for a girl.
- Measured Height < -2.5 Standard Deviation
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Pubertal signs ie: testis volume > or = 4 ml in boys and breast stage > or = B2
(Tanner)
- Serious chronic disease (diabetes, renal insufficiency, heart failure, hepatic
insufficiency, neoplasia)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Fetal Growth RetardationStudy Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
NCT00174252
- Amiens,
- ANGERS Cedex 03,
- Besançon,
- Bordeaux,
- Bron Cedex,
- Caen Cedex 5,
- Dunkerque Cedex 1,
- Lille,
- Limoges Cedex,
- Lorient,
- Nice,
- PARIS Cedex 19,
- Paris,
- Paris,
- Rennes,
- Rouen,
- Strasbourg,
- Tarbes,
- Toulouse,
- Toulouse,
- Tours,
- Vandoeuvre Les Nancy,
ALL GENDERS
4 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age | |||
| Official Title ICMJE | Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation. | |||
| Brief Summary | To estimate the percentage of children with serum IGF-1 > 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Fetal Growth Retardation | |||
| Intervention ICMJE | Drug: Genotonorm (Somatropin)
0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years | |||
| Study Arms ICMJE | Experimental: Genotonorm (Somatropin)
Intervention: Drug: Genotonorm (Somatropin) | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 57 | |||
| Original Enrollment ICMJE | 100 | |||
| Actual Study Completion Date ICMJE | April 2009 | |||
| Actual Primary Completion Date | April 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 4 Years to 9 Years (Child) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | France | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00174252 | |||
| Other Study ID Numbers ICMJE | A6281234 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | June 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||